胰岛素样生长因子-1衍生物的分子设计与药物开发

摘要
图/表
参考文献(0)
相关文章 (2)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要

胰岛素样生长因子-1（IGF-1）广泛参与细胞增殖、分化和凋亡等生理过程，参与许多正常和疾病状态的生理现象；重组人IGF-1已用于治疗原发性IGF-1缺陷引发的侏儒症。为了使IGF-1更具成药优势，扩大应用范围，扩展其安全性与有效性，科研人员正在积极开发IGF-1的衍生物和类似物。介绍了采用分子设计的技术手段开发的IGF-1衍生物，截短型IGF-1和加长型IGF-1，IGF-1及衍生物与 IgG1 的 Fc 片段的融合蛋白，聚乙二醇化的IGF-1等。提出基于IGF-1衍生物分子优良的药动学和药效学特性，体内半衰期长、生物活性高的新型IGF-1药物一定会在将来临床应用中发挥重要作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	贾寅星

关键词 ：胰岛素样生长因子-1（IGF-1）, 衍生物, 药物

Abstract：

Insulin-like growth factor-1(IGF-1) is involved in cell proliferation, differentiation and apoptosis in a wide range,and has also been shown to be associated with some types of normal and diseased physiological processes. The recombinant human IGF-1 has been used to treat children dwarfism caused by severe deficiency of primary IGF-1. In order to expand range of applications and safety and effectiveness of IGF-1, researchers are actively developing IGF-1 derivatives and analogs. IGF-1 derivatives developed through a number of technological strategies were introduced which included truncated IGF-1 and lengthened IGF-1, or the fusion of the Fc domain of IgG1 to IGF-1 and IGF-1 derivatives, or construction of pegylated IGF-1. It is pointed out that based on the modifiable molecular structure and pharmacokinetic and pharmacodynamic properties of recombinant IGF-1 derivatives, it is hopeful that more IGF-1 drugs with prolonged half-life and increased bioactivity will be developed to meet the modern clinical demands.

Key words： insulin-like growth factor-1 derivatives drug

作者简介: 贾寅星（1986—），男，河北石家庄人，助理工程师。E-mail：15176977878@163.com

引用本文:

贾寅星. 胰岛素样生长因子-1衍生物的分子设计与药物开发[J]. 煤炭与化工, 2015, 38(4): 30-34，134. JIA Yin-xing. Molecular Design and Drug Development of IGF-1 Derivatives. CCI, 2015, 38(4): 30-34，134.

链接本文:

http://www.mtyhg.com.cn/CN/ 或 http://www.mtyhg.com.cn/CN/Y2015/V38/I4/30

[ 1 ]    Cephalon inc. Treating disorders by application of insulin-like growth factors and analogs : US，5652214[ P ]. 1997-07-29.
[ 2 ]     特西卡股份有限公司.胰岛素样生长因子-1（IGF-1 ）缺陷的治疗方法：CN, 200480030864.2[ P ]. 2006-11-29.
[ 3 ]     Durai R, Yang W，Gupta S，et al. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge[ J ]. Int J Colorectal Dis，2005，20（3 ）：203 - 220.
[ 4 ]     Velloso CP. Regulation of muscle mass by growth hormone and IGF-I[ J ]. Br J Pharmacol，2008，154（3 ）：557 - 568.
[ 5 ]      Zhang L，Smith DW，Gardiner BS，et al. Modeling the nsulin-Like GrowthFactor System in Articular Cartilage[ J ]. PLoS One，2013，8（6 ）：e66 870.
[ 6 ]     Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity[ J ]. J Clin Endocrinol Metab, 2007, 92（3 ）：902-910.
[ 7 ]     Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease[ J ]. Growth Horm IGF Res，2003 ,13（4 ）：113-170.
[ 8 ]     Genentech inc. Formulated IGF-I Composition：US, 5681814[ P ].1997-10-28.
[ 9 ]     Celtrix pharma. Therapeutic uses of human somatomedin carrier proteins：US，5681818[ P ]. 1997-10-28.
[ 10 ]   伊西康公司.含生长因子的凝胶制剂：CN，96198773.1[ P ]. 1999-03-17.
[ 11 ]   Genentech inc. method of enhancing geowth in patients using combination therapy：US,5126324[ P ].1992-06-30.

[ 12 ]    罗伯特弗朗西斯肖.使用功能性屏障治疗和修复软骨或骨缺损或损伤的方法及组合物：CN, 97196887.X[ P ].1999-08-25.
[ 13 ]     Bard inc C R. Composition and method for revitalizing scar tissue :US，5686425[ P ]. 1997-11-11.
[ 14 ]    Chiron corp.Compositions and methods of therapy for IGF-I-responsive conditions: US, 20030100505[ P ]. 2003-05-29.
[ 15 ]    Tercica inc. Methods of reducing visceral fat by increasing levels of insulin-like growth factor-I (IGF-I):US,20050043240[ P ].2005-02-24.
[ 16 ]    基因技术股份有限公司.IGF-1的结晶：CN, 02804707.9[ P ].2005-11-30.
[ 17 ]    Groprp Pty LTD. Peptide Analogues of Insulin-like Growth Factor 1 ( IGF-1 ) or Factor 2 ( IGF-2 )：US, 5164370 [ P ]. 1992-11-17.
[ 18 ]    Genentech inc. Method of Enhancing Growth in Patients using Combination Therapy：US, 5126324[ P ]. 1992-06-30.
[ 19 ]    Genentech inc. IGF-1 to improve the neural condition：US, 5861373 [ P ]. 1999-01-19.
[ 20 ]    Gropep Pty Ltd. Growth Factor：US, 5077276[ P ]. 1991-12-31.
[ 21 ]    Pharmacia AB. Truncated IGF-I: WO, 9633216[ P ]. 1996-10-24.
[ 22 ]    Univ Jefferson. IGF-1 analogs：US，5473054[ P ]. 1995-12-05.
[ 23 ]    凯尔杰有限公司.具有胰岛素样生长因子-I活性的肽及其用途，CN，200780007937.X[ P ]. 2009-03-25.
[ 24 ]    参天制药株式会社. 新型肽及其药物用途:CN, 02824164.9[ P ].2005-03-23.
[ 25 ]    诺瓦提斯公司.稳定的胰岛素样生长因子多肽:CN,200780021376.9[ P ].2009-06-24.
[ 26 ]    GROPEP PTY LTD. Method for treating intestinal diseases : US，5679771[ P ]. 1997-10-21.
[ 27 ]    朱成钢. 长链人胰岛素样生长因子( LR3IGF-1 )及其制备和应用方法：ZL，200710003418.8[ P ].2007-08-01
[ 28 ]    埃斯特瑞恩有限公司. 胰岛素样生长因子融合蛋白:CN，200880110332.8[ P ].2010-09-08.
[ 29 ]    益普生制药股份有限公司. 在第59位置处具有氨基酸替换的胰岛素样生长因子-1（IGF-1 ）类似物：CN，201080041981.4[ P ]. 2012-06-20.
[ 30 ]    Regeneron Pharmaceuticals, inc.Method of treating a muscle-related condition with modified IGF1 polypeptides:US，2008199479[ P ]. 2008-08-21.
[ 31 ] Regenron Pharmaceuticals, inc. IGF-I and IGF-2 chimeric polypeptides and therapeutic uses thereof:US，2009175864[ P ]. 2009-07-09
[ 32 ]   Regeneron Pharmaceuticals, inc. IGF-I fusion polypeptides and therapeutic uses thereof：US,2006166328 [ P ]. 2006-07-27.
[ 33 ]    江苏普罗赛生物技术有限公司. 哺乳动物细胞大规模生产重组人IGF1-Fc融合蛋白的实验技术：CN，201110274233.7[ P ]. 2012-08-01.
[ 34 ]    Veronese FM, Pasut G. PEGylation, successful approach to drug  delivery[ J ]. Drug Discov Today, 2005,10（21 ）：1451-1458.
[ 35 ]    弗·哈夫曼-拉罗切有限公司.胰岛素样生长因子-1（IGF-1 ）和聚乙二醇的缀合物:CN, 200580048506. 9[ P ]. 2008-02-13.
[ 36 ]    弗·哈夫曼-拉罗切有限公司.制备胰岛素样生长因子-1与聚（乙二醇）的偶联物的方法：CN, 200780031987. 1[ P ]. 2009-08-19.
[ 37 ]    山景医药公司. 具有保留的受体结合活性的细胞因子、趋化因子、生长因子、多肽激素及其拮抗剂的聚合物缀合物,CN, 200380109611.X[ P ]. 2006-11-08.
[ 38 ]    霍夫曼-拉罗奇有限公司. IGF-1聚乙二醇缀合物,CN, 201180008318.9[ P ]. 2012-10-17.